Euro DEHP RA (risk assessment) by June?
This article was originally published in Clinica
The European Union's routine risk assessment of DEHP, the softener used in PVC medical devices, could be into its final stages by early June. That is when the next sitting of the quarterly "technical meeting on existing chemicals" is held, in Arona, Italy. Member state representatives attending the last meeting, in mid-March, requested more time to review new findings on toxicity in rats, by Schilling (2002), a two-generation study in rats, and those contained in a report presented to the US Society of Toxicology meeting in Nashville on March 20. EU member states have until April 19 to put forward their final position.
You may also be interested in...
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.